You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)推介材料:预测明年增长50%以上
阿思达克 10-21 17:11
药明生物(02269.HK)今日股价抽高11.6%收225元,成升幅最大蓝筹股。根据药明生物网站的推介材料,昨公司发布一份面向投资者的资料截至10月15日止公司汇报期内共新增72个项目,有23个项目进入後期。

公司於10月至今总未交付订单达到103亿美元(约为798.26亿港元)。公司预计明年增长可达50%以上,料受惠新冠疫苗及单抗,并相信於2022年可续保持较高增长。

此外,麦格理发表研究报告指,药明生物首席执行官昨日举行了投资者会议,并将今年下半年盈利增长指引由30%升至40%,而2021及2022年的增长指引则由逾40%增至逾50%。(wl/k)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account